Lanstead Capital Completes £6 Million Subscription in ImmuPharma

Lanstead Capital Investors L.P. ("Lanstead") recently announced its £6 million subscription for 100,000,000 new ordinary shares in ImmuPharma PLC (LSE AIM: IMM) ("ImmuPharma") at 6.0 pence per share, together with an associated sharing agreement. The subscription forms part of a wider fundraise by ImmuPharma, which includes a retail offer to raise up to an additional £1.5 million, for total gross proceeds of up to £7.5 million.

Orrick represented Lanstead.

THE COMPANY

Lanstead Capital Investors L.P. is a long-standing investor in ImmuPharma and has committed £6 million to fund the accelerated development of Kapiglucagon, representing its largest single investment into ImmuPharma over the last 10 years.

THE IMPACT

ImmuPharma is a specialist drug discovery and development company quoted on AIM, recognised for P140, its lead programme in autoimmune diseases. The company is also advancing Kapiglucagon, a proprietary form of glucagon for the treatment of Type 1 diabetes designed for use in next-generation dual-hormone artificial pancreas systems.

Pursuant to the subscription, Lanstead will receive 100,000,000 new ordinary shares and will enter into a sharing agreement with ImmuPharma, under which the £6 million gross proceeds will be pledged by the company and returned to it over 20 monthly settlements, subject to adjustment based on share price performance against a benchmark price of 8.0 pence per share. Lanstead will also receive 12,000,000 new ordinary shares as value payment shares in connection with the sharing agreement. On completion, Lanstead will hold approximately 17.5 per cent. of ImmuPharma's enlarged issued share capital (assuming the retail offer is fully subscribed). Admission is expected on or around 8 April 2026, subject to shareholder approval at a general meeting.

THE TEAM

The Orrick team was led by Ed Lukins, supported by Abigail Parkin.

LEARN MORE

• Read more Orrick client results